CorMedix Inc.  

(Public, NYSEMKT:CRMD)   Watch this stock  
Find more results for CRMD
5.73
-0.27 (-4.50%)
After Hours: 5.71 -0.02 (-0.35%)
May 22, 7:34PM EDT  
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 5.71 - 6.03
52 week 1.05 - 10.40
Open 6.00
Vol / Avg. 633,610.00/712,288.00
Mkt cap 184.07M
P/E     -
Div/yield     -
EPS -0.42
Shares 27.86M
Beta -1.16
Inst. own 15%
May 8, 2015
Q1 2015 CorMedix Inc Earnings Call
May 7, 2015
Q1 2015 CorMedix Inc Earnings Release
Mar 13, 2015
Q4 2014 CorMedix Inc Earnings Release
Mar 13, 2015
Q4 2014 CorMedix Inc Earnings Call
Mar 10, 2015
CorMedix Inc at ROTH Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -17586.92% -10806.48%
Operating margin -17584.55% -6004.50%
EBITD margin - -4695.44%
Return on average assets -296.99% -507.18%
Return on average equity -395.11% -
Employees 5 -
CDP Score - -

Address

1430 US Highway 206 Ste 200
BEDMINSTER, NJ 07921-4602
United States - Map
+1-908-5179500 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

CorMedix Inc. (CorMedix) is a development-stage specialty pharmaceutical company. The Company in-licenses, develops and commercializes therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases, specifically in the dialysis and non-dialysis areas. The Company has in-licensed all of the products in its pipeline. The company has the worldwide rights to develop and commercialize product candidates, CRMD003 (Neutrolin) and CRMD004, which address potentially large market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology and total parenteral nutrition patients.

Officers and directors

Cora M. Tellez Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Randy Milby Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
Harry O'Grady Chief Financial Officer
Age: 53
Bio & Compensation  - Reuters
Antony E. Pfaffle M.D. Chief Scientific Officer, Director
Age: 51
Bio & Compensation  - Reuters
Matthew P. Duffy Independent Director
Age: 52
Bio & Compensation  - Reuters
Michael W. George Independent Director
Age: 66
Bio & Compensation  - Reuters
Steven W. Lefkowitz Independent Director
Age: 59
Bio & Compensation  - Reuters
Taunia S. Markvicka Pharm.D. Independent Director
Age: 46
Bio & Compensation  - Reuters